Development and Validation of the Isotretinoin Hesitancy Scale for Acne Vulgaris: A Preliminary Study

Basit Öğe Kaydı
dc.authoridAgaoglu, Esra/0000-0001-8985-6224
dc.contributor.authorAgaoglu, Esra
dc.contributor.authorKaraman, Imran Gokcen Yilmaz
dc.contributor.authorKacar, Cennet Yastibas
dc.contributor.authorErdogan, Hilal Kaya
dc.contributor.authorMutlu, Talha
dc.contributor.authorKaradag, Ayse Serap
dc.date.accessioned2025-01-06T17:36:04Z
dc.date.available2025-01-06T17:36:04Z
dc.date.issued2024
dc.description.abstractBackground: Oral isotretinoin is the most effective systemic treatment for acne patients who fail to respond to other forms of therapies. However, hesitations and concerns regarding its side effect profile may detain the patients from treatment. This study aimed to develop and validate the Isotretinoin Hesitancy Scale (IHS) among acne patients. Methods: A cross- sectional study was conducted with 100 acne patients who had not used isotretinoin previously. A 22- item scale was created based on the related literature and expert opinions. The items of the scale related to beliefs and worries about isotretinoin were formatted with response options: agree, indecisive, and disagree. In this study, construct validity was tested with exploratory factor analysis, and reliability was tested with internal consistency and split- half reliability. Results: The results of exploratory factor analysis indicated a three- factor solution with a total of 14 items, explaining 57% of the total variance. The first factor (Hesitancy Related to Reversible Adverse Effects: 6 items) accounted for 30% of the variance, the second factor (Hesitancy Related to Irreversible Adverse Effects: 4 items) accounted for 16% of the variance and the third factor (Isotretinoin- related Anxiety: 4 items) accounted 11% of the variance. The internal consistency of the three factors was calculated as 0.79, 0.78, and 0.72, respectively. The Cronbach's alpha score of the total scale was found to be 0.81, and split- half reliability was found to be 0.87. Conclusions: The IHS is the first scale that provides a valid and reliable assessment of isotretinoin hesitancy in acne patients. Eliminating isotretinoin hesitancy may reduce acne- related clinical and psychosocial consequences.
dc.identifier.doi10.1111/jocd.16589
dc.identifier.issn1473-2130
dc.identifier.issn1473-2165
dc.identifier.pmid39291853
dc.identifier.scopus2-s2.0-85204475235
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1111/jocd.16589
dc.identifier.urihttps://hdl.handle.net/20.500.14669/1739
dc.identifier.wosWOS:001315126400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Cosmetic Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241211
dc.subjectacne vulgaris
dc.subjecthesitancy
dc.subjectisotretinoin
dc.subjectscale
dc.subjecttreatment
dc.titleDevelopment and Validation of the Isotretinoin Hesitancy Scale for Acne Vulgaris: A Preliminary Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu